Streamlining Biktarvy Prior Authorization for Gastroenterology Practices

The Administrative Burden of Biktarvy Prior Authorization

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) consistently ranks as a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. Regardless of the prescribing specialty, managing its PA process requires diligent documentation, timely submission, and robust tracking to prevent treatment delays and revenue cycle interruptions. Klivira's platform is designed to automate these demands, ensuring all necessary data is compiled and submitted accurately.

High-Volume Prior Authorization Categories in Gastroenterology

Gastroenterology practices contend with a significant volume of prior authorizations concentrated in several key areas. These include biologics for inflammatory bowel disease (IBD), hepatitis C direct-acting antivirals, advanced diagnostic imaging, and specific endoscopic procedures. The complexity of these PAs requires deep understanding of clinical guidelines and payer policies.

Key Documentation for Gastroenterology Prior Authorizations

• For IBD biologics (e.g., Humira, Stelara, Entyvio, Skyrizi): Diagnosis confirmation, disease severity (Mayo score, CDAI), prior conventional therapy trials (5-ASA), TB/hepatitis screening, and step therapy compliance per ACG/AGA guidelines.
• For Hepatitis C DAAs (e.g., Epclusa, Mavyret): Genotype, fibrosis stage (FibroSure, transient elastography), prior treatment history, and drug-drug interaction review per AASLD guidelines.
• For advanced imaging (e.g., MRCP, CT enterography): Clear clinical question, prior imaging history, and completion of conservative evaluation workup.
• For capsule endoscopy (CPT 91110): Documentation of prior workup (upper GI series, EGD), specific indication (obscure GI bleeding, IBD evaluation), and adherence to payer medical necessity criteria.
• For specialty functional-GI drugs (e.g., Viberzi, Linzess): Diagnosis criteria (Rome criteria for IBS) and documentation of prior conservative therapy trials.

Common Prior Authorization Denials in Gastroenterology

Denials in GI prior authorization frequently stem from non-adherence to payer-mandated step therapy for IBD biologics, requiring failure of conventional therapy or specific TNF inhibitors before non-TNF agents. Other common reasons include insufficient documentation of disease severity (e.g., missing Mayo score), incomplete pre-biologic screening (TB, hepatitis), fibrosis-stage documentation gaps for Hep C DAAs, and lack of clinical correlation for advanced imaging requests.

Addressing Diverse Prior Authorization Needs in GI Workflows

While Biktarvy is not typically prescribed for a primary GI indication, a gastroenterology practice may still encounter its prior authorization through co-managed patients or within a broader health system's centralized PA operations. Managing such diverse PA requirements efficiently, alongside the high-volume, complex PAs for GI-specific biologics and procedures, underscores the need for an integrated automation platform. Klivira ensures consistent, accurate PA processing across all medication types.

Klivira's Comprehensive Approach to Gastroenterology Prior Authorization

Klivira's platform is engineered to address the unique complexities of GI prior authorization, including the challenges of managing non-GI specific medications like Biktarvy. Our system incorporates ACG/AGA-guideline-aware step therapy logic for IBD biologics, automates treatment-status classification from EMR medication history, and streamlines Hep C DAA workflows with genotype and fibrosis stage documentation. We also manage periodic re-authorization for chronic treatments and facilitate medical-vs-pharmacy benefit routing for biologics, ensuring efficient processing for all PA types a GI practice encounters.